Skip to content
Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer

Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer

Get the podcast

MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSC

The Audio Journal of Oncology

MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSCLC) in a single-arm phase two study reported at the 2018 annual congress of the European Society for Medical Oncology, ESMO.

http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=felip

“The information presented here showed that for patients included in the ASCEND 3 trial—ALK positive patients previously treated with chemotherapy—who received ceritinib as their first ALK inhibitor there [was] an overall survival of 51 months. This is really encouraging,” said lead author Enriqueta Felip MD PhD, medical oncologist and Chair of the Thoracic Malignancies Group at Vall d’Hebron University Hospital in Barcelona, Spain, talking to the Audio Journal of Oncology.

Tags

ceritinibEnriqueta FelipESMO 2018lung cancerMandate ALK testing in lung cancerTargeted therapy lung cancer

Next in ESMO 2018

All 11 interviews

Interview 11 of 11

Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib

Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib

BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) w

15 October 2018

Related Episodes